A study of patients with nonmetastatic prostate cancer suggests that MRSI parameters can predict risk for biochemical recurrence after radical prostatectomy.
In a randomized trial, cabazitaxel significantly improved clinical outcomes in certain patients with metastatic CRPC.
Docetaxel Added to Hormone Therapy Benefits Survival in Metastatic Hormone-Sensitive Prostate Cancer
Long-term follow-up demonstrates a persistent benefit in survival with docetaxel for patients with metastatic hormone-naïve prostate cancer.
Results from a second interim analysis of the phase 3 SPARTAN study show apalutamide is tied to a 25% reduction in risk for death versus placebo in nonmetastatic CRPC.
The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.
In patients with metastatic, hormone-sensitive prostate cancer undergoing testosterone suppression, enzalutamide was tied to significantly longer PFS and OS than standard care.
Enzalutamide combined with ADT significantly reduced the risk for metastatic progression or death in men with metastatic hormone-sensitive prostate cancer.
The FDA has approved darolutamide for the treatment of patients with nonmetastatic CRPC.
True or false: Salvage radiotherapy combined with short-term hormone therapy significantly improved metastatic-free survival compared with salvage radiotherapy alone in patients who underwent…